South San Francisco Newswire (Page 3)

Comprehensive Real-Time News Feed for South San Francisco, CA. (Page 3)

Results 41 - 60 of 92 for "u:bizjournals.com" in South San Francisco, CA

  1. Clarus Ventures seeks $375 million for third life sciences fundRead the original story

    Feb 10, 2014 | Business Journal

    Cambridge, Mass.-based Clarus Ventures is raising $375 million for a third fund, part of a $2 billion or more surge in life sciences VC funds.

    Comment?

  2. How San Francisco plans to get to 30,000 new housing unitsRead the original story

    Feb 7, 2014 | Business Journal

    San Francisco Mayor Ed Lee has a plan for the city to build or rehab 30,000 housing units by 2020.

    Comment?

  3. Obama 'myRA' plan gives unintended shout-out to Crescendo Bio rheumatoid arthritis appRead the original story

    Jan 30, 2014 | Business Journal

    Not that employees of the South San Francisco developer of a rheumatoid arthritis diagnostic test need a retirement plan.

    Comment?

  4. KaloBios shares tank on failed asthma drug trialRead the original story

    Jan 30, 2014 | Business Journal

    Shares of KaloBios Pharmaceuticals Inc. lost more than a quarter of their value Thursday after the South San Francisco company said its experimental asthma drug failed in a Phase II study.

    Comment?

  5. Obama retirement plan gives unintended shout-out to Crescendo Bio rheumatoid arthritis appRead the original story

    Jan 30, 2014 | Business Journal

    Not that employees of the South San Francisco developer of a rheumatoid arthritis diagnostic test need a retirement plan.

    Comment?

  6. Fluidigm Corp. to buy DVS Sciences in genomics, proteomics mergerRead the original story

    Jan 29, 2014 | Business Journal

    South San Francisco-based Fluidigm makes microfluidic systems used in genomics and proteomics type research in laboratories at universities, drug companies and agricultural businesses.

    Comment?

  7. Exelixis targets drug trial costs with stock offeringRead the original story

    Jan 22, 2014 | Business Journal

    Exelixis Inc. could raise $80 million to $90 million in an overnight stock offering of 10 million or more shares as it tries to fund several late-stage cancer drug studies and starts to pay down debt, the drug developer said Wednesday.

    Comment?

  8. Exelixis targets drug trial costs with stock offeringRead the original story

    Jan 22, 2014 | Business Journal

    Exelixis Inc. could raise $80 million to $90 million in an overnight stock offering of 10 million or more shares as it tries to fund several late-stage cancer drug studies and starts to pay down debt, the drug developer said Wednesday.

    Comment?

  9. Lennar taps the Mark Co. for Shipyard marketingRead the original story

    Jan 21, 2014 | Business Journal

    Lennar Corp. has enlisted the Mark Co. to do the sales and marketing for the first release of the San Francisco Shipyard, a 775-acre development located along nine miles of the San Francisco waterfront.

    Comment?

  10. Free ride may be over for employee shuttles in San FranciscoRead the original story

    Jan 21, 2014 | Business Journal

    This map shows the route that private shuttles take out of San Francisco to Peninsula-based employers.

    Comment?

  11. PATH hires former White House AIDS advisor Grant ColfaxRead the original story

    Jan 14, 2014 | Business Journal

    PATH, the Seattle-based Program for Appropriate Technology in Health, an international nonprofit, hired Grant Colfax , M.D., to oversee its work on HIV/AIDS and tuberculosis.

    Comment?

  12. Fluidigm hits Q4 revenue of about $21 millionRead the original story

    Jan 14, 2014 | Business Journal

    That puts the South San Francisco company ahead of the same quarter a year earlier, when it had revenue of $15.7 million.

    Comment?

  13. Five Prime, Adimab ink deal around potential cancer treatmentsRead the original story

    Jan 9, 2014 | Business Journal

    Five Prime Therapeutics Inc. closed its second collaboration since it went public in September, bagging a deal around antibodies that could stimulate the immune system to attack cancer cells.

    Comment?

  14. CytomX inks cancer drug deal with ImmunoGenRead the original story

    Jan 9, 2014 | Business Journal

    Venture-backed CytomX Therapeutics Inc. cut a deal with ImmunoGen Inc. in the hot drug-development space known as antibody-drug conjugates.

    Comment?

  15. Licensing deals add 2 blood cancer drugs to Sunesis pipelineRead the original story

    Jan 9, 2014 | Business Journal

    Both drugs are not yet in the clinic, said South San Francisco-based Sunesis , but both were developed under a research deal between Biogen Idec and Sunesis.

    Comment?

  16. Compugen cancer work leads to South S.F. expansionRead the original story

    Jan 7, 2014 | Business Journal

    A growing number of companies, buoyed by the work of Genentech Inc. and other drug developers, are looking at ways to stimulate the immune system as a way of fighting cancer.

    Comment?

  17. Tech commuter buses will pay to use San Francisco Muni stopsRead the original story

    Jan 6, 2014 | Business Journal

    Under a new pilot plan shuttles that carry thousands of San Franciscans to tech jobs on the Peninsula will have to pay to use Muni bus stops based on a per stop, per day formula that could raise an estimated $1.5 million.

    Comment?

  18. Study enrollment translates into $12.5 million Threshold paydayRead the original story

    Jan 2, 2014 | Business Journal

    Threshold Pharmaceuticals Inc. will receive $12.5 million from partner Merck KGaA after enrollment in a late-stage trial of the South San Francisco company's experimental cancer-fighting drug hit 620 patients.

    Comment?

  19. Best Bay Area life sciences CEOs of 2013Read the original story

    Dec 27, 2013 | Business Journal

    Bonnie Anderson Veracyte Inc. Here's the thing about Veracyte: Anderson and the crew at the South San Francisco molecular diagnostics company could have happily held onto their cash after the commercial launch of the Afirma thyroid test, but they decided to build a multiple-product company rather than a one-hit wonder.

    Comment?

  20. Theravance to pay GSK $60M after FDA approval, launch of COPD drugRead the original story

    Dec 19, 2013 | Business Journal

    Theravance Inc. will pay partner GlaxoSmithKline plc $30 million after regulatory approval Wednesday of a once-daily treatment for the lung condition chronic obstructive pulmonary disease.

    Comment?

South San Francisco Job Listings
View or post South San Francisco job listings on Topix.
South San Francisco Real Estate
News, listings, and foreclosures in South San Francisco from Topix.
South San Francisco Mortgages
Find mortgage rates in South San Francisco on Topix.